BIOTRICITY, INC. The Future of Real-Time Outpatient
Monitoring
September 2022
NASDAQ - BTCY
Important Cautions Regarding Forward Looking Statements:
Certain information contained in this presentation includes "forward-looking statements." Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition and results of operations, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our existing and proposed business, including many assumptions regarding future events. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors, including those risks described in detail in the section entitled "Risk Factors" in the June 22, 2021 Form 10-K, as well as elsewhere herein.
Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology.
In light of these risks and uncertainties, and especially given the nature of our existing and proposed business, there can be no assurance that the forward-looking statements contained in this presentation and elsewhere will in fact occur. Potential investors should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.
THE FUTURE OF REAL-TIME OUTPATIENT MONITORING | PRIVATE & CONFIDENTIAL - FOR INTERNAL USE ONLY | 2022 |
Biotricity - Corporate Summary
- Improving quality of care and saving lives with a revolutionary product portfolios and business model, targeting a multi-Billion-dollar TAM 3, 4
- Selling proprietary FDA approved Cardiac monitoring solution today across 29 states utilizing it daily with new sites/cardiologists added every month.
- Recurring revenue business model across existing and future products Technology-as-a-Service (TaaS)
- Products are insurance reimbursable (US)
- Triple digit growth YoY, even with COVID 1
- Proven "go to market" sales and operations models and with a global cellular IoT platform (global FCC ID)
- New complementary product portfolio rolling out in 2022 with pilot sites already active, designed to go deeper into existing customers
- Recently received FDA clearance and launched Biotres product
- Launched Biokit, a personal medical device kit
- Well capitalized to support growth initiatives, over 2,000 physicians using our product.
- Increased the company's TAM from $1B to $35B with product ecosystem in the last 6 months!
- https://www.biotricity.com/biotricity-reports-record-quarter-earns-1-0-million-in-quarterly-revenue-for-the-first-time/
2https://www.grandviewresearch.com/industry-analysis/cardiovascular-devices-market
3,4https://www.medgadget.com/2021/01/remote-cardiac-monitoring-services-market-foreseen-to-accrue-usd-1-39-billion-global-industry-research-size-share-major-segments-leading-companies-and-competitive-analysis-through-2027.html
THE FUTURE OF REAL-TIME OUTPATIENT MONITORING | PRIVATE & CONFIDENTIAL - FOR INTERNAL USE ONLY | 2022 |
Cardiac Market Opportunity
- As of 2018, approximately 30M Americans have received a diagnosis 1
- Physicians need an integrated approach, within their practice, that allows them to diagnose and prescribe monitoring equipment to patients with multiple comorbidities
- Physicians need to actively monitor data from compromised patients to trigger real-time intervention, reduce patient risk and physician liability through faster diagnosis
- https://www.healthline.com/health/heart-disease/statistics
- https://www.medgadget.com/2021/01/remote-cardiac-monitoring-services-market-foreseen-to-accrue-usd-1-39-billion-global-industry-research-size-share-major-segments-leading-companies-and-competitive-analysis-through-2027.html
THE FUTURE OF REAL-TIME OUTPATIENT MONITORING | PRIVATE & CONFIDENTIAL - FOR INTERNAL USE ONLY | 2022 |
Problem: Cardiac Care
- Cardiac Care is disjointed with different solutions from different vendors
- Cardiac issues are intermittent, and patients are often asymptomatic, requiring long-term data with connectivity
- Most solutions are passive, i.e. not real time recording devices
- Post procedure patients and high-risk patients should remain under observation with real-time RPM
- Lack cross compatibility with other devices/solutions
- Long-term,continuous monitoring results in better detection of early warning signs in an illness, decreasing hospital admission rates 1
- Effective use of RPM allows physicians to see more patients, perform more procedures, and identify which patients need more time and attention 2
- https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.111.088971
- https://news.careinnovations.com/blog/how-rpm-empowers-clinicians-to-treat-more-patients-via-exception-based-management
3https://www.marketsandmarkets.com/Market-Reports/remote-patient-monitoring-market-77155492.html
140
120
100
80
60
40
20
0
$117.1B
$23.2B
Global Remote Patient Monitoring
2020 | 2025 | |
THE FUTURE OF REAL-TIME OUTPATIENT MONITORING | PRIVATE & CONFIDENTIAL - FOR INTERNAL USE ONLY | 2022 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Biotricity Inc. published this content on 07 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 September 2022 19:39:01 UTC.
